These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 34002069)

  • 21. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
    Fizazi K; Smith MR; Tombal B
    Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advanced Androgen Blockage in Nonmetastatic Castration-resistant Prostate Cancer: An Indirect Comparison of Apalutamide and Enzalutamide.
    Wallis CJD; Chandrasekar T; Goldberg H; Klotz L; Fleshner N; Satkunasivam R; Klaassen Z
    Eur Urol Oncol; 2018 Aug; 1(3):238-241. PubMed ID: 31102627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
    Zhang F; Lu YP
    Zhonghua Nan Ke Xue; 2020 Apr; 26(4):364-368. PubMed ID: 33351306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Schultz NM; O'Day K; Sugarman R; Ramaswamy K
    J Manag Care Spec Pharm; 2020 Apr; 26(4):538-549. PubMed ID: 32020841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of enzalutamide and apalutamide in the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC): a multicenter retrospective study.
    Hara S; Mori K; Fukuokaya W; Tomomasa N; Oguchi T; Takahashi Y; Saito S; Katami J; Sano T; Kadena S; Hashimoto M; Yata Y; Nishi E; Suhara Y; Takamizawa S; Kurawaki S; Suzuki H; Miyajima K; Iwatani K; Urabe F; Ito K; Yanagisawa T; Tsuzuki S; Shimomura T; Kimura T
    Int J Clin Oncol; 2024 Aug; 29(8):1191-1197. PubMed ID: 38769191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer.
    Brave M; Weinstock C; Brewer JR; Chi DC; Suzman DL; Cheng J; Zhang L; Sridhara R; Ibrahim A; Kluetz PG; Pazdur R; Beaver JA
    Clin Cancer Res; 2020 Sep; 26(18):4717-4722. PubMed ID: 32284318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Apalutamide, Erleada®].
    Sautois B; Denis C
    Rev Med Liege; 2022 Oct; 77(10):609-615. PubMed ID: 36226398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of novel hormonal therapies in the management of non-metastatic castration-resistant prostate cancer: a literature-based meta-analysis of randomized trials.
    Roviello G; Gatta Michelet MR; D'Angelo A; Nobili S; Mini E
    Clin Transl Oncol; 2020 Jul; 22(7):1033-1039. PubMed ID: 31617061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study.
    Stenzl A; Dunshee C; De Giorgi U; Alekseev B; Iguchi T; Szmulewitz RZ; Flaig TW; Tombal B; Morlock R; Ivanescu C; Ramaswamy K; Saad F; Armstrong AJ
    Eur Urol; 2020 Oct; 78(4):603-614. PubMed ID: 32336645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
    Halabi S; Jiang S; Terasawa E; Garcia-Horton V; Ayyagari R; Waldeck AR; Shore N
    J Urol; 2021 Aug; 206(2):298-307. PubMed ID: 33818140
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer.
    Rajaram P; Rivera A; Muthima K; Olveda N; Muchalski H; Chen QH
    Molecules; 2020 May; 25(10):. PubMed ID: 32456317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy, Prognostic Factors, and Safety Profile of Enzalutamide for Non-metastatic and Metastatic Castration-Resistant Prostate Cancer: A Retrospective Single-Center Analysis in Japan.
    Fujiwara M; Yuasa T; Komai Y; Numao N; Yamamoto S; Fukui I; Yonese J
    Target Oncol; 2020 Oct; 15(5):635-643. PubMed ID: 33037973
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
    Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
    Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of enzalutamide and apalutamide in the treatment of non-metastasic castration-resistant prostate cancer: Indirect comparison.
    Nieto-Gómez P; Ubago-Pérez R; Cabeza-Barrera J
    Actas Urol Esp (Engl Ed); 2019 Sep; 43(7):355-363. PubMed ID: 31133348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring.
    Saad F; Sternberg CN; Efstathiou E; Fizazi K; Modelska K; Lin X; Sugg J; Steinberg J; Noerby B; Shore ND; Hussain M
    Eur Urol; 2020 Dec; 78(6):847-853. PubMed ID: 33010985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.
    Saad F; Cella D; Basch E; Hadaschik BA; Mainwaring PN; Oudard S; Graff JN; McQuarrie K; Li S; Hudgens S; Lawson J; Lopez-Gitlitz A; Yu MK; Smith MR; Small EJ
    Lancet Oncol; 2018 Oct; 19(10):1404-1416. PubMed ID: 30213449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apalutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.
    Al-Salama ZT
    Drugs; 2019 Sep; 79(14):1591-1598. PubMed ID: 31489589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses.
    Armstrong AJ; Shore ND; Szmulewitz RZ; Petrylak DP; Holzbeierlein J; Villers A; Azad A; Alcaraz A; Alekseev B; Iguchi T; Gomez-Veiga F; Rosbrook B; Lee HJ; Haas GP; Stenzl A
    J Urol; 2021 May; 205(5):1361-1371. PubMed ID: 33356529
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancer.
    Fizazi K; Albiges L; Loriot Y; Massard C
    Expert Rev Anticancer Ther; 2015; 15(9):1007-17. PubMed ID: 26313416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solid cancer: the new tumour spread endpoint opens novel opportunities.
    Fernandes M; Rosel D; Brábek J
    Br J Cancer; 2019 Oct; 121(7):513-514. PubMed ID: 31427682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.